Metronidazol Vioser

Metronidazole, the active ingredient in Metronidazol Vioser, is a nitroimidazole antibiotic presented as an intravenous formulation for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in adults and children as prescribed.

GNH USA supplies Metronidazol Vioser as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazol Vioser is indicated for a range of anaerobic and protozoal infections. It targets the underlying microorganisms to eradicate infection and improve clinical outcomes.

- Anaerobic bacterial infections: effective against mixed anaerobic infections, reducing bacterial load. - Bacterial vaginosis: restores normal vaginal flora by eliminating pathogenic anaerobes. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms. - Intra‑abdominal infections: controls polymicrobial intra‑abdominal sepsis. - Pelvic inflammatory disease: treats anaerobic components of PID. - Clostridioides difficile‑associated diarrhea: reduces toxin‑producing bacteria in the colon.

Metronidazol Vioser may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Metallic taste - Headache - Diarrhea

Serious or Rare Side Effects: - Seizures - Peripheral neuropathy - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome

Before initiating therapy, consider patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust dose as recommended by prescriber. - Hepatic dysfunction: monitor liver function tests. - Alcohol consumption: avoid during therapy due to disulfiram‑like reaction. - Pregnancy: Category B; use only if benefit outweighs risk. - Duplicate therapy: avoid concurrent use of other metronidazole‑containing products. - Store at ambient temperature: keep in original container, protect from light and moisture.

Metronidazol Vioser can interact with several medicines; some require avoidance, others close monitoring.

Major Interactions (Avoid): - Alcohol: may cause severe nausea and vomiting (disulfiram‑like reaction). - Warfarin: may potentiate anticoagulant effect, increasing INR. - Lithium: may raise lithium levels, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenobarbital: may reduce metronidazole levels. - Oral contraceptives: may reduce efficacy; advise additional contraception.